Medical Information Only. Consult your healthcare provider before considering clinical trial enrollment.
Ampullary Cancer: early-phase trial registry
2 of 3 indexed Ampullary Cancer trials are currently recruiting, with more weight in Phase 1-2.
Corpus placement: #5,209 of 28,707 conditions by registered trial count.
3 US clinical trials · 2 currently recruiting · #5,209 of 28,707 conditions by registered trial count
Ampullary Cancer: 3 US clinical trials tracked, 2 recruiting.
Ampullary Cancer is the subject of 3 registered US clinical trials on ClinicalTrials.gov, 2 of them currently open to new participants. 0 are in Phase 3-4 (later-stage) and 1 in Phase 1-2 (earlier-stage). The most active sponsor is Compass Therapeutics, running 1 of these trials.
Enrollment posture brief
Registry condition ampullary-cancer
OPEN 2 | RECR 67% | LATE 0 | EARLY 1 | RANK #5209 | SPON 1
Volume-matched condition peers
Nearest open-share peer: Acute Hypoxemic Respiratory Failure (67% recruiting · 6 trials)
Ampullary Cancer lists 2 open slots (67% of 3 indexed trials). Peers are matched on registered volume, not therapeutic-area browse lists. How peer matching works →
Key findings
What ClinicalTrials.gov does not surface for Ampullary Cancer on its own pages , computed from the registry mirror as of 2026-08-08. Each line carries its own denominator so it can be quoted as it stands.
-
Ampullary Cancer is recruiting above its size-band peers.
2 of 3 indexed trials (66.7%) are open to enrollment, against a 46.5% average across 27,806 conditions with fewer than 20 trials. The peer set uses the same ClinicalTrials.gov-derived counts as this page.
Open and recent trials
3 total, page 1 of 1
Individualized Dose Escalation of 5-FU for Gastrointestinal Cancer
Dartmouth-Hitchcock Medical Center
NCT05780684
Pilot Comparing ctDNA IDV vs. SPV Sample in Pts Undergoing Biopsies for Hepatobiliary and Pancreatic Cancers
University of California, Irvine
NCT05497531
A Study of CTX-009 in Combination With Paclitaxel in Adult Patients With Unresectable Advanced, Metastatic or Recurrent Biliary Tract Cancers (COMPANION-002)
Compass Therapeutics
NCT05506943
Phase Distribution
| Phase | Trial count |
|---|---|
| Phase 2 | 1 |
Top Sponsors
Named interventions
Most-linked intervention names on Ampullary Cancer records (sponsor-reported on ClinicalTrials.gov). Counts are trial links, not unique products.
US sites by state
Facility locations filed on Ampullary Cancer trials. A trial with sites in several states counts in each.
Source: ClinicalTrials.gov, National Library of Medicine. Data is informational only.
Related
What to do with this Ampullary Cancer page
3 registered trials, 2 currently recruiting, is a starting point for a conversation, not a diagnosis or a recommendation.
- 2 Ampullary Cancer trials are currently recruiting, check eligibility criteria before contacting a site. Browse recruiting trials
- Compass Therapeutics sponsors the most Ampullary Cancer trials on record, review their full trial history before evaluating a specific study. See Compass Therapeutics's trials
- Bring the specific trial ID (NCT number) to your own doctor before enrolling, this page is a directory, not medical guidance. Read the trial-finding guide
Trial and recruiting counts reflect ClinicalTrials.gov registry status as of the data vintage above; individual trial eligibility and enrollment status can change.
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This Ampullary Cancer condition card totals 3 registered trials; most-linked intervention FOX dose-escalation algorithm; top US site state California. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.